Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (381-390 of 463) with videos related to

Pageof 47
Sort By:
Journal of Inflammation Research|November 24, 2025
Association Between Maternal IBD-Related Antibodies and Early Life Gut Inflammatory Status and Microbiota Composition: Insights from Cord BloodTaegyu Kim, Paola Nicoletti, Maria Manuela Estevinho, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Maternal IBD-related antibodies are associated with early life gut inflammatory status and microbiota composition: insights from cord bloodTaegyu Kim, Paola Nicoletti, Maria Manuela Estevinho, et al.
Gastroenterology|December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Gastroenterology|December 27, 2017
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's DiseaseJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
Crohn'S & Colitis 360|March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseaseQuazim A Alayo, Marc Fenster, Osama Altayar, et al.
Journal of Crohn'S & Colitis|June 6, 2023
Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel DiseaseJoão Sabino, Leonid Tarassishin, Caroline Eisele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 17, 2020
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC ConsortiumMarc Fenster, Quazim A Alayo, Aava Khatiwada, et al.
The American Journal of Gastroenterology|June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY ConsortiumParambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor AgentsJordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|May 3, 2014
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's diseaseSylvie Rajca, Virginie Grondin, Edouard Louis, et al.
Pageof 47

Showing results (381-390 of 463) with videos related to

Sort By:
Pageof 47
Journal of Inflammation Research|November 24, 2025
Association Between Maternal IBD-Related Antibodies and Early Life Gut Inflammatory Status and Microbiota Composition: Insights from Cord BloodTaegyu Kim, Paola Nicoletti, Maria Manuela Estevinho, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Maternal IBD-related antibodies are associated with early life gut inflammatory status and microbiota composition: insights from cord bloodTaegyu Kim, Paola Nicoletti, Maria Manuela Estevinho, et al.
Gastroenterology|December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Gastroenterology|December 27, 2017
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's DiseaseJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
Crohn'S & Colitis 360|March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseaseQuazim A Alayo, Marc Fenster, Osama Altayar, et al.
Journal of Crohn'S & Colitis|June 6, 2023
Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel DiseaseJoão Sabino, Leonid Tarassishin, Caroline Eisele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 17, 2020
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC ConsortiumMarc Fenster, Quazim A Alayo, Aava Khatiwada, et al.
The American Journal of Gastroenterology|June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY ConsortiumParambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor AgentsJordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|May 3, 2014
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's diseaseSylvie Rajca, Virginie Grondin, Edouard Louis, et al.
Pageof 47